AlphaMaven AlphaMaven

Stanley Druckenmiller, Dan Loeb and 12 Other Big Funds Sold Danaher Last Quarter, While 26 Bought. Who’s Right?

Reported by Tikr
Nov 20, 2026· 3 min read
Save Post LinkedIn Email
Key Takeaways
  • • Of 460 large funds that filed 13Fs for the quarter ended Sept. 30, 2026, 26 bought Danaher (DHR) and 14 sold it, including Stanley Druckenmiller's Duquesne Family Office and Dan Loeb's Third Point, which exited their positions.
  • • Buyers committed far more capital: Dodge & Cox led with about $2.18 billion of added shares, taking its stake to 10.08 million shares from 257,039.
  • • Lone Pine Capital opened a 4.94 million-share Danaher position worth about $1.10 billion, and Maverick Capital opened a 2.21 million-share position worth about $490 million.
  • • Danaher's third-quarter sales rose 8.5% to $6.55 billion and adjusted EPS rose 11.5% to $2.11, and the company raised 2026 adjusted EPS guidance to $8.57-$8.62, while the stock trades at about 25x forward earnings versus a five-year average of 27x.
Summary
According to TIKR.com's analysis of 13F filings for the quarter ended Sept. 30, 26 of 460 large funds bought Danaher (DHR) and 14 sold or cut their holdings by 20% or more, while 65 held the position. Sellers generally held small positions relative to their portfolios. Duquesne Family Office sold all 50,300 shares, about $10 million, equal to 0.2% of its 13F stocks in June, and Third Point exited 540,000 shares, about $103 million, or 2.2% of its June 13F stocks. Generation Investment Management made the largest dollar sale, cutting its stake 25% to 5.09 million shares worth about $369 million, though Danaher remained its second-largest holding at 12.0% of its $9.4 billion US equity portfolio. Dorsey Asset Management fully exited 626,211 shares, a position that had been 7.6% of its 13F stocks in June.

Buyers deployed substantially more capital. Dodge & Cox, which manages $467 billion, lifted its stake to 10.08 million shares from 257,039, roughly $2.18 billion, though this was only 1.2% of its 13F stocks. Lone Pine Capital, a $22 billion hedge fund, opened a 4.94 million-share position worth about $1.10 billion, making Danaher its second-largest holding at 7.1% of its 13F stocks. Lee Ainslie's Maverick Capital opened 2.21 million shares worth about $490 million. Viking Global opened a position worth about $231 million, Tiger Global nearly tripled its stake to 1.27 million shares, and D1 Capital added 32% to 3.02 million shares. Lone Pine and Maverick also opened new positions in Thermo Fisher Scientific (TMO) worth $673 million and $201 million, while Duquesne fully exited its Thermo Fisher stake. Because 13F filings only show holdings at quarter-end dates, the timing and rationale of these trades cannot be determined.

On fundamentals, Danaher reported third-quarter results on Oct. 21 that beat estimates, with sales up 8.5% and core revenue up 3.0% (5.5% excluding respiratory testing), according to its release. The company raised 2026 adjusted EPS guidance to $8.57-$8.62 from $8.45-$8.60. TIKR reports that 24 analysts covering the stock have an average price target of $259.90, about 14% above the last close, and that analysts expect normalized EPS of $10.29 by 2028. The stock trades at 25x forward earnings, below its five-year average of 27x and its August 2024 peak of 35x, though it fell as low as 19x in May. TIKR's view is that the buyers have the stronger case, while noting the main risk is slower core growth outside respiratory testing, with guidance calling for 4% to 5% in the fourth quarter. The fourth-quarter report is expected in late January, and 13Fs for the quarter ending Dec. 31 are due in mid-February.

Go deeper than the headline

Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.

Start your free 7-day trial

Sources

1 outlet

AlphaMaven summarised this story from the reporting below. Each link opens the original article.

Tikr Stanley Druckenmiller, Dan Loeb and 12 Other Big Funds Sold Danaher Last Quarter, While 26 Bought. Who’s Right?